Anti-CSC Effects in Human Esophageal Squamous Cell Carcinomas and Eca109/9706 Cells Induced by Nanoliposomal Quercetin Alone or Combined with CD 133 Antiserum

  • Zheng, Nai-Gang (Molecular Cell Biology Research Center, Medical College of Zhengzhou University) ;
  • Mo, Sai-Jun (Molecular Cell Biology Research Center, Medical College of Zhengzhou University) ;
  • Li, Jin-Ping (Molecular Cell Biology Research Center, Medical College of Zhengzhou University) ;
  • Wu, Jing-Lan (Molecular Cell Biology Research Center, Medical College of Zhengzhou University)
  • Published : 2014.11.06


CD133 was recently reported to be a cancer stem cell and prognostic marker. Quercetin is considered as a potential chemopreventive agent due to its involvement in suppression of oxidative stress, proliferation and metastasis. In this study, the expression of CD133/CD44 in esophageal carcinomas and Eca109/9706 cells was explored. In immunoflurorescence the locations of $CD133^+$ and multidrug resistance 1 $(MDR1)^+$ in the same E-cancer cells were coincident, mainly in cytomembranes. In esophageal squamous cell carcinomas detected by double/single immunocytochemistry, small $CD133^+$ cells were located in the basal layer of stratified squamous epithelium, determined as CSLC (cancer stem like cells); $CD44^+$ surrounding the cells appeared in diffuse pattern, and the larger $CD44^+$ (hi) cells were mainly located in the prickle cell layer of the epithelium, as progenitor cells. In E-cancer cells exposed to nanoliposomal quercetin (nLQ with cytomembrane permeability), down-regulation of NF-${\kappa}Bp65$, histone deacetylase 1 (HDAC1) and cyclin D1 and up-regulation of caspase-3 were shown by immunoblotting, and attenuated HDAC1 with nuclear translocation and promoted E-cadherin expression were demonstrated by immunocytochemistry. In particular, enhanced E-cadherin expression reflected the reversed epithelial mesenchymal transition (EMT) capacity of nLQ, acting as cancer attenuator/preventive agent. nLQ acting as an HDAC inhibitor induced apoptotic cells detected by TUNEL assay mediated via HDAC-NF-${\kappa}B$ signaling. Apoptotic effects of liposomal quercetin (LQ, with cytomembrane-philia) combined with CD133 antiserum were also detected by CD133 immunocytochemistry combined with TUNEL assay. The combination could induce greater apoptotic effects than nLQ induced alone, suggesting a novel anti-CSC treatment strategy.


  1. Bertrand J, Begaud-Grimaud G, Bessette B, et al (2009). Cancer stem cells from human glioma cell line are resistant to Fasinduced apoptosis. Int J Oncol, 34, 717-27.
  2. Almanaa TN, Geusz ME, Jamasbi RJ, et al (2012). Effects of curcurmin on stem-like cells in human esophageal squamous carcinoma cell lines. BMC Complement Altern Med, 12, 195.
  3. Aomatsu N, Yashiro M, Kashiwagi S, et al (2012). CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One, 7, 45865.
  4. Bao S, Wu Q, Li Z, et al (2008). Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res, 68, 6043-48.
  5. Bu Y, Cao D (2012). The origin of cancer stem cells. Front Biosci, 4, 819-30.
  6. Cai J, Guan H, Fang L, et al (2013). MicroRNA-374a activates Wnt/$\beta$-catenin signaling to promote breast cancer metastasis. J Clin Invest, 123, 566-79.
  7. Carcia Bueno JM, Ocaiia A, Gastro-Garcia P, et al (2008). An update on the biology of cancer stem cells in breat cancer. Clin Transl Oncol, 10, 786-93.
  8. Cetin I, Topcul M (2012). Cancer stem cells in oncology. J BUON, 17, 644-8.
  9. Dreeson O, Brivanlou AH (2007). Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev, 3, 7-17.
  10. Charpentier MS, Whipple RA, Vitolo MI, et al (2014). Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment. Cancer Res, 74, 1250-60.
  11. Chen YC, Hsu HS, Chen YW, et al (2008). Oct-4 expression maintained caner stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE, 3, 2637.
  12. Chu P, Clanton DJ, Snipas TS, et al (2009). Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer, 124, 1312-21.
  13. Galizia G, Cemei M, Del Vecchio L, et al (2012). Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg, 147, 18-24.
  14. Gil J, Stembalska A, Pesz KA, Sasiadek MM (2008). Cancer stem cells: the theory and perspectives in cancer therapy. J Appl Genet, 49, 193-99.
  15. Gong CC, Zheng NG, Wu JL, et al (2009). Mechanism of quercetin anti-oxidative effect on NIH-3T3 cells in vitro and on rats in vivo. Basic Clin Med, 29, 52-8.
  16. Guo JX, Tao QS, Lou PR, et al (2012). miR-181b as a potential molecular target for anticancer therapy of gastric neoplasms. Asian Pac J Cancer Prev, 13, 2263-7.
  17. Hori Y (2013). Promini-1 (CD133) reveals new faces of pancreatic progenitor cells and cancer stem cells: current knowledge and therapeutic perspectives. Adv Exp Med Biol, 777, 185-96.
  18. Hu L, Cao D, Li Y, et al (2012). resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cellsmediated cytolysis through NKG2D ligands and TRAIL receptors. Cancer Biol Ther, 13, 516-26.
  19. Knudson CB (2003). Hyaluronan and CD44: strategic players for cell-matrix interactions during chondrogenesis and matrix assembly. Birth Defects Res Part C: Embryo Today, 69, 174-96.
  20. Jin ZH, Sogawa C, Furukawa TY et al (2012). Basic studies on radioimmunotargeting of CD133-positive HCT116 cancer stem cells. Mol Imaging, 11, 445-50.
  21. Kobel M, Weichert W, Cruwell K, et al (2004). Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adennocarcinomas and linked to patient prognosis. Virchows Arch, 445, 456-64.
  22. Kokkinos MI, Murthi P, Wafai R, et al (2010). Cadherins in the human placenta-epithelial-mesenchymal transition (EMT) and placental development. Placenta, 31, 747-55.
  23. Lehmann A, Denkert C, Budczies J, et al (2009). High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer, 9, 395.
  24. Park MH, Choi MS, Kwak DH, et al (2011). Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-$\kappa{B}$. Prostate, 71, 801-12.
  25. Pellacani D, Oldridge EE, Collins AT, Maitland NJ (2013). Promini-1 (CD133) expression in the prostate and prostate cancer: a marker for quiescent stem cells. Adv Exp Med Biol, 777, 167-84.
  26. Pincelli C, Marconi A (2010). Keratinocyte stem cells: friends and foes. J Cell Physiol, 225, 310-5.
  27. Pincelli C, Marconi D, Milsom C, Magnus N, et al (2010). Role of the tissue factor pathway in the biology of tumor initiating cells. Thromb Res, 125, 44-50.
  28. Pirozzi G, Tirino V, Camerlingo R, et al (2013). Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer. Oncol Rep, 29, 1763-8.
  29. Song W, Li H, Tao K, et al (2008). Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract, 62, 1212-8.
  30. Puglisi MA, Sgambato A, Saulnier N F, et al (2009). Isolation and characterization of $CD133^+$ cell population within human primary and metastatic colon cancer. Eur Rev Med Pharmacol Sci, 1, 55-62.
  31. Seidel C, Schnekenburger M, Dicato M, Diederich M (2012). Histone deacetylase modulators provided by mother nature. Genes Nutr, 7, 357-67.
  32. Simon RA, di Sant'Agnese PA, Huang LS, et al (2009). CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol, 40, 252-8.
  33. Sun WJ, Zhou X, Zheng JH, et al (2012). Histone acetyltransferases and deacetylases: molecular and clinical implications to gastro- intestinal carcinogenesis. Acta Biochim Biophys Sin, 44, 80-91.
  34. Steliou K, Boosalis MS, Perrine SP, et al (2012). Butyrate histone deacetylase inhibitors. Biores Open Access, 1, 192-8.
  35. Tabu K, Bizen N, Taga T, Tanaka S (2013). Gene regulation of Prominin-1(CD133) in normal and cancerous tissues. Adv Exp Med Biol, 777, 73-85.
  36. Thomas SN, Zhu F, Schnaar PL, et al (2008). Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. J Biol Chem, 283, 15647-55.
  37. Tong QS, Zheng LD, Tang ST, et al (2008). Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr, 4, 58-62.
  38. Wertz IE, Dixit VM (2010). Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb Perspect Biol, 2, 3350.
  39. Tunnon MJ, Garcia-Mediavilla MV, Sanchez-Campos S, Gonzalez-Gallego J (2009). Potential of flavonoids as antiinflammatory agents: modulation of pro- inflammatory gene expression and signal transduction pathways. Curr Drug Metab, 10, 256-71.
  40. Wang F, Qi Y, Li X, et al (2013). HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9. Clin Invest Med, 36, 87-94.
  41. Wang K, Xu J, Zhang J, Huang J, et al (2012). Prognostic role of CD133 expression in colorectal cancer: a meta-analysis. BMC Cancer, 12, 573.
  42. Zhang Qinxian, Zheng Naigang, Zhang Ying, et al (2007). Redox-evolution of Eca-109 cells by 8-Br-cAMP and quercetin and correlation with p16ss DNA binding nuclear matrix protein. Life Sci J, 4, 1-7.
  43. Zheng Naigang, Wang Li, Wu Jinglan, et al (2008). Rapid enrichment of stem cell population by filter screening and biomarker-immunoassays from human epidermis. Life Sci J, 5, 33-7.

Cited by

  1. Effect of CXCR4 and CD133 Co-expression on the Prognosis of Patients with Stage II~III Colon Cancer vol.16, pp.3, 2015,